ERBB2 and breast cancer: Despite the lack of high-level medical evidence supporting trastuzumab monotherapy as a treatment for metastatic breast cancer, significant clinical benefits have been highlighted in a phase II clinical study in the treatment of advanced breast cancer with HER-2 gene immunohistochemical scores of >3 or positive FISH tests (15).